indirect immunofluorescence: 1-2 μg/mL using human HeLa cells. western blot: 0.5-1.0 μg/mL using whole extracts of HEK-293T cells over-expressing human PLAUR.
Plasminogen activator urokinase receptor (PLAUR)/ urokinase plasminogen activator receptor (uPAR), a member of Ly6/ neurotoxin receptor family, is a heavily glycosylated glycosyl-phosphatidylinositol (GPI)-anchored cell-surface receptor. It is comprised of serine protease uPA, specific inhibitors (plasminogen activator inhibitors 1 and 2) and three internally disulfide-bonded domains (D1, D2 and D3).
Immunogen
peptide corresponding to a sequence at the C-terminus of human PLAUR, conjugated to KLH. The corresponding sequence is identical in monkey PLAUR.
Application
Anti-PLAUR antibody produced in rabbit has been used in immunoblotting and immunofluorescence.
Biochem/physiol Actions
Plasminogen activator urokinase receptor (PLAUR)/ urokinase plasminogen activator receptor (uPAR) acts as a receptor for urokinase plasminogen activator (uPA). It localizes and promotes plasmin formation. uPAR influences many normal and pathological processes related to cell surface plasminogen activation, degradation of the extracellular matrix, cell migration, leukocyte adhesion, chemotaxis and signal transduction during leukocyte recruitment from the circulation to extravascular sites of inflammation. It is implicated as an anti-cancer target. uPAR is involved in epilepsy, language, cognition, communication and central nervous system disorders.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy
Mazar AP
Clinical Cancer Research, 14(18), 5649-5655 (2008)
uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy
K Lund I, et al.
Current Drug Targets, 12(12), 1744-1760 (2011)
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review
Bene MC, et al.
Leukemia, 18(3), 394-394 (2004)
The role of the urokinase receptor in epilepsy, in disorders of language, cognition, communication and behavior, and in the central nervous system
Bruneau N and Szepetowski P
Current Pharmaceutical Design, 17(19), 1914-1923 (2011)
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.